Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Amgen Inc (NASDAQ:AMGN)

171.47
Delayed Data
As of Jul 29
 -1.27 / -0.74%
Today’s Change
122.25
Today|||52-Week Range
174.80
+7.65%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$131.3B

Company Description

Amgen, Inc. is a biotechnology medicines company, which discovers, develops, manufactures and markets medicines for grievous illnesses. The company focuses on human therapeutics and concentrates on innovating novel medicines based on advances in cellular and molecular biology. It markets recombinant protein therapeutics in supportive cancer care, nephrology and inflammation. The cpmpany's products include Neulasta, a pegylated protein, based on the Filgrastim molecule and NEUPOGEN, a recombinant-methionyl human granulocyte colony stimulating factor both of which selectively stimulate the production of neutrophils; Enbrel, an inhibitor of tumor necrosis factor, a substance that plays a role in the body's response to inflammatory diseases; Sensipar/Mimpara, a small molecule calcimimetic that lowers serum calcium levels; Vectibix, a monoclonal antibody that binds specifically to the epidermal growth factor receptor; and Nplate, a thrombopoietin receptor agonist that mimics endogenous TPO, the primary driver of platelet production. Amgen was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Contact Information

Amgen, Inc.
1 Amgen Center Drive
Thousand Oaks California 91320-1799
P:(805) 447-1000
Investor Relations:
(805) 447-1060

Employees

Shareholders

Mutual fund holders50.85%
Other institutional32.64%
Individual stakeholders0.64%

Top Executives

Robert A. BradwayChairman, President & Chief Executive Officer
Madhu BalachandranExecutive Vice President-Operations
David W. MelineChief Financial Officer & Executive Vice President
Sean E. HarperExecutive Vice President-Research & Development
Diana L. McKenzieChief Information Officer & Senior Vice President